Dr. Garren’s extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company’s ...

On September 13, 2023, Hideki Garren, the Chief Medical Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 2,000 shares of the company.

DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational ...